Arturas Kalniunas
Biographic Data
| ID | 7959846 |
|---|---|
| NAME | Arturas Kalniunas |
| GIVEN NAMES | Arturas |
| FAMILY NAME | Kalniunas |
| SIGNATURE | KALNIUNAS A |
| AFFILIATIONS | Greater Manchester Mental Health NHS Foundation Trust |
| ORCID | 0000-0003-1002-6194 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Non-verbal behaviours as predictors for treatment response in patients with depression or schizophrenia
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022368599
Cariprazine in the management of emotionally unstable personality disorder in female patients
This is the first case series to evaluate the effectiveness of cariprazine in EUPD. Its efficacy in improving PANSS and CGI-S scores was overall modest and highly variable, reflective of an inherently heterogenous and comorbid patient sample but the benefits on treatment perseverance and tolerability were considerable. Cariprazine may be of particular benefit in EUPD where psychotic symptoms are co-morbid, as an augmentation strategy to clozapine…
Cariprazine for negative symptoms in early psychosis
This pilot study suggests that cariprazine is a safe and effective treatment in early psychosis, particularly for the alleviation of negative symptoms which remains an area of unmet treatment need
No prominent works on this page.
Cariprazine for negative symptoms in early psychosis
This pilot study suggests that cariprazine is a safe and effective treatment in early psychosis, particularly for the alleviation of negative symptoms which remains an area of unmet treatment need
Cariprazine in the management of emotionally unstable personality disorder in female patients
This is the first case series to evaluate the effectiveness of cariprazine in EUPD. Its efficacy in improving PANSS and CGI-S scores was overall modest and highly variable, reflective of an inherently heterogenous and comorbid patient sample but the benefits on treatment perseverance and tolerability were considerable. Cariprazine may be of particular benefit in EUPD where psychotic symptoms are co-morbid, as an augmentation strategy to clozapine…
Non-verbal behaviours as predictors for treatment response in patients with depression or schizophrenia
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022368599
Schizophrenia research and treatment (3 works) · Psychiatry (2 works) · Psychology (2 works) · Adverse effect (1 work) · Agonist (1 work) · Antipsychotic (1 work) · Bipolar Disorder and Treatment (1 work) · Borderline personality disorder (1 work) · Clinical Psychology (1 work) · Clinical Psychology (1 work)